Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $105.00 at Stifel Nicolaus

Key Points

• Stifel Nicolaus cut its price target on Zimmer Biomet to $105 (from $110) but kept a "buy" rating, an implied upside of ~28%; the MarketBeat consensus average target is about $104.14 with a consensus rating of "Hold".
• Q1 results beat expectations — adjusted EPS $2.09 and revenue ~$2.09B (up ~9.3% y/y) — and the company raised FY‑2026 adjusted EPS guidance to $8.40–$8.55.
• Despite the beat, shares fell to roughly $81.79 and underperformed peers as investor concern over a CFO departure and executive turnover weighed on the stock, which is trading near its 52‑week low.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective lowered by stock analysts at Stifel Nicolaus from $110.00 to $105.00 in a note issued to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a "buy" rating on the medical equipment provider's stock. Stifel Nicolaus' price objective suggests a potential upside of 28.38% from the company's previous close.

ZBH has been the topic of several other research reports. Evercore raised Zimmer Biomet from an "in-line" rating to an "outperform" rating and lifted their price objective for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Leerink Partners assumed coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They issued a "hold" rating and a $101.00 price target on the stock. BTIG Research reaffirmed a "neutral" rating on shares of Zimmer Biomet in a report on Monday, March 23rd. Weiss Ratings raised shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday, April 7th. Finally, The Goldman Sachs Group cut shares of Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 price target for the company. in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $104.14.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $1.01 during mid-day trading on Wednesday, reaching $81.79. The company had a trading volume of 311,710 shares, compared to its average volume of 2,234,336. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The firm has a market cap of $15.83 billion, a price-to-earnings ratio of 22.93, a PEG ratio of 1.89 and a beta of 0.61. The company has a 50 day moving average of $93.23 and a 200-day moving average of $92.89. Zimmer Biomet has a 52 week low of $80.38 and a 52 week high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating analysts' consensus estimates of $1.86 by $0.23. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.06 billion. During the same quarter in the prior year, the business earned $1.81 earnings per share. The firm's revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, sell-side analysts expect that Zimmer Biomet will post 8.39 EPS for the current fiscal year.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares of the company's stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.28% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. DV Equities LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $25,000. Key Financial Inc raised its position in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. lifted its stake in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock valued at $29,000 after acquiring an additional 116 shares during the period. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the fourth quarter valued at about $30,000. Finally, Root Financial Partners LLC acquired a new stake in Zimmer Biomet in the third quarter worth about $31,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 results beat expectations: adjusted EPS $2.09 and revenue ~$2.09B (up ~9.3% y/y); company raised FY‑2026 adjusted EPS guidance to $8.40–$8.55, signaling stronger underlying demand and margin expansion. Read More.
• Neutral Sentiment: Earnings call / transcripts provide color on product momentum, salesforce changes and margin drivers — useful for modeling near-term organic growth and cost outlook. Read More. • Read More.
• Negative Sentiment: Executive turnover spooked investors: CFO Suketu Upadhyay departed effective April 28 and an interim CFO was named — headlines and coverage of leadership exits coincided with a sharp intraday selloff (reports note a plunge to a multi‑year low). Read More. • Read More.
• Negative Sentiment: Despite the beat, shares underperformed peers and dipped in pre‑market trading — suggests investor focus on leadership risk and valuation vs. near‑term volatility rather than the quarter itself. Read More. • Read More.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.